Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
HUTCHMED (China) Limited - American Depositary Shares
(NQ:
HCM
)
14.13
+0.21 (+1.51%)
Delayed Quote
Updated: 2:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about HUTCHMED (China) Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
Today 8:35 EST
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
November 04, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
November 01, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
October 28, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
October 26, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
October 26, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
October 25, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
October 20, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
September 28, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
September 27, 2026
First-in-class KRAS-payload leveraging synchronized EGFR inhibition
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
September 23, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 03, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
August 30, 2026
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
August 27, 2026
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
August 16, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2026 Interim Results
July 30, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
July 02, 2026
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2026 Half-Year Financial Results
June 30, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
June 24, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
June 11, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
May 21, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 21, 2026
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
April 08, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
March 22, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 09, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
March 06, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2025 Full Year Results and Business Updates
March 05, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
